Abstract
AbstractNew drug introductions are key to growth for pharmaceutical firms. However, not all innovations are the same and they may have differential effects that vary by firm size. We use quarterly sales data on UK pharmaceuticals in a dynamic panel model to estimate the impact of product (new drugs) and marketing (additional pack varieties) innovations within a therapeutic class on a firm’s business unit growth. We find that product innovations lead to substantial growth in both the short and long run, whereas a new pack variety only produces short-term effects. The strategies are substitutes but the marginal effects are larger for product innovations relative to additional packs, and the effects are larger for smaller business units. Nonetheless, pack introductions offer a viable short-term growth strategy, especially for small- and medium-sized businesses.
Publisher
Springer Science and Business Media LLC
Subject
Economics and Econometrics,General Business, Management and Accounting
Reference84 articles.
1. Acs, Z.J., & Audretsch, D.B. (1988). Innovation in large and small firms: an empirical analysis. The American Economic Review, 78(4), 678–690. http://www.jstor.org/stable/1811167.
2. Acs, Z.J., & Audretsch, D.B. (1990). Innovation and small firms. Cambridge: MIT Press. ISBN: 9780262011136.
3. Agarwal, R. (1997). Survival of firms over the product life cycle. Southern Economic Journal, 63(3), 571–584. https://doi.org/10.2307/1061095, http://www.jstor.org/stable/1061095.
4. Aghion, P., & Howitt, P. (1992). A model of growth through creative destruction. Econometrica, 60(2), 323–351. https://doi.org/10.2307/2951599.
5. Akcigit, U. (2010). Firm size, innovation dynamics and growth. Working paper (University of Pennsylvania), https://economics.sas.upenn.edu/events/firm-size-innovation-dynamics-and-growth.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献